We serve Chemical Name:2-Phenylnaphthalene CAS:612-94-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Phenylnaphthalene
CAS.NO:612-94-2
Synonyms:EINECS 210-324-6;2-phenylnaphthalene;MFCD00039601
Molecular Formula:C16H12
Molecular Weight:204.26600
HS Code:29334990
Physical and Chemical Properties:
Melting point:105 °C
Boiling point:358 °C
Density:1.081g/cm3
Index of Refraction:1.647
PSA:
Exact Mass:204.09400
LogP:4.50680
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 210-324-6 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00039601 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 210-324-6 Use and application,EINECS 210-324-6 technical grade,usp/ep/jp grade.
Related News: Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 2-Phenylnaphthalene manufacturer The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market. 2-Phenylnaphthalene supplier Under the plan, nonessential hospital staff members who belong to the union would not go to work on Monday. 2-Phenylnaphthalene vendor Under the plan, nonessential hospital staff members who belong to the union would not go to work on Monday. 2-Phenylnaphthalene factory Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.